Amgen At Supreme Court: What’s The Threshold For Securities Fraud?
This article was originally published in The Pink Sheet Daily
Executive Summary
Justices address whether plaintiffs need to prove company misrepresentations are material at the class certification stage; pension funds claim Amgen misrepresented the safety of Aranesp and Epogen prior to an FDA advisory committee meeting.
You may also be interested in...
Amgen Wins Supreme Court Review Of EPO Securities Fraud Class Certification
The court will decide whether a party seeking class certification must show that a company’s alleged misrepresentations are material; investors claim Amgen misrepresented the safety of Aranesp and Epogen prior to a May 2004 FDA advisory committee meeting.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.